secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001558370-22-002741
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics reports cash $90.3M; Phase 3 uproleselan data still after 2022
----------------------------------------------------------------------------

- Cash and equivalents $90.3M at Dec 31, 2021 vs $137.0M at Dec 31, 2020; revenue fell to $1.2M from $10.2M.
- Pivotal Phase 3 uproleselan trial in relapsed/refractory AML completed enrollment (388 patients); top-line data expected after year-end 2022.
- NCI Phase 2/3 registration trial (newly diagnosed AML) completed Phase 2 enrollment (267 patients); interim analysis planned.
- Apollomics initiated Phase 3 uproleselan trial in Greater China in November 2021 after Breakthrough Therapy designation.
- Expanded executive team: hired Lisa DeLuca (VP Regulatory), Bruce Johnson (SVP/Chief Commercial Officer), Deepak Tiwari (VP Technical Operations).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022002741/0001558370-22-002741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022002741/glyc-20220303x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-002741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer